维奈托克与去甲基化药物在伴原始细胞增多的骨髓增生异常综合征中的真实世界经验。 - Suppr

Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.

作者信息

Gangat Naseema, McCullough Kristen, Johnson Isla, Al-Kali Aref, Begna Kebede H, Patnaik Mrinal M, Litzow Mark R, Hogan William, Shah Mithun, Alkhateeb Hassan, Mangaonkar Abhishek, Foran James M, Badar Talha, Palmer Jeanne M, Sproat Lisa, Arana Yi Cecilia Y, Pardanani Animesh, Tefferi Ayalew

机构信息

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

Division of Hematology, Mayo Clinic, Jacksonville, Florida, USA.

出版信息

Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24.

DOI:10.1002/ajh.26539

PMID:35303376

Abstract

摘要

相似文献

Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.维奈托克与去甲基化药物在伴原始细胞增多的骨髓增生异常综合征中的真实世界经验。

Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24.

Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective.维奈托克与去甲基化药物治疗骨髓增生异常综合征：全景视角

Am J Hematol. 2023 Feb;98(2):225-228. doi: 10.1002/ajh.26781. Epub 2022 Nov 25.

An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.阿扎胞苷联合维奈克拉治疗骨髓增生异常综合征的早期观察

Lancet Haematol. 2022 Oct;9(10):e714-e716. doi: 10.1016/S2352-3026(22)00252-6. Epub 2022 Sep 2.

Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.骨髓增生异常综合征适合使用维奈克拉吗？探索未来潜力与考量因素。

Expert Rev Hematol. 2021 Sep;14(9):789-793. doi: 10.1080/17474086.2021.1968822. Epub 2021 Aug 26.

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.评估维奈托克联合去甲基化药物在高危骨髓增生异常综合征中的作用。

Blood Cancer J. 2022 Nov 4;12(11):148. doi: 10.1038/s41408-022-00744-z.

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.维奈托克联合低甲基化药物治疗高危骨髓增生异常综合征：真实世界经验的回顾性评估。

Leuk Lymphoma. 2020 Nov;61(11):2700-2707. doi: 10.1080/10428194.2020.1775214. Epub 2020 Jun 16.

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with mutations.维奈托克与阿扎胞苷联合治疗伴有突变的骨髓增生异常综合征。

Hematology. 2024 Dec;29(1):2338509. doi: 10.1080/16078454.2024.2338509. Epub 2024 Apr 10.

The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.venetoclax 联合低甲基化药物治疗急性髓系白血病和骨髓增生异常综合征患者的疗效和不良事件：系统评价和荟萃分析。

Hematology. 2020 Dec;25(1):414-423. doi: 10.1080/16078454.2020.1843752.

Prospects for Venetoclax in Myelodysplastic Syndromes. Venetoclax 在骨髓增生异常综合征中的应用前景。

Hematol Oncol Clin North Am. 2020 Apr;34(2):441-448. doi: 10.1016/j.hoc.2019.10.005. Epub 2019 Dec 11.

A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.高危骨髓增生异常综合征和急性髓系白血病患者用维奈克拉治疗的真实土耳其经验。

Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):e686-e692. doi: 10.1016/j.clml.2021.04.004. Epub 2021 Apr 20.

引用本文的文献

Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome.骨髓增生异常综合征中修订版与分子国际预后评分系统风险不一致的影响

Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02760-x.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.去甲基化药物联合维奈克拉用于高危骨髓增生异常综合征和慢性粒-单核细胞白血病作为移植的桥接治疗：一项GESMD研究

Exp Hematol Oncol. 2025 Apr 26;14(1):61. doi: 10.1186/s40164-025-00652-5.

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.口服地西他滨联合西扎珠利定（有或无维奈克拉）治疗高危骨髓增生异常综合征或慢性粒单核细胞白血病：一项倾向评分匹配研究

Blood Cancer J. 2025 Mar 31;15(1):50. doi: 10.1038/s41408-025-01245-5.

Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.维奈托克联合低甲基化药物与强化化疗治疗新诊断的伴有骨髓发育异常相关改变的急性髓系白血病：基于国际共识分类的倾向评分匹配分析

Blood Cancer J. 2024 Aug 23;14(1):144. doi: 10.1038/s41408-024-01130-7.

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics.针对具有不良遗传学特征的急性髓系白血病的精准医学方法。

Int J Mol Sci. 2024 Apr 11;25(8):4259. doi: 10.3390/ijms25084259.

[Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world].维奈克拉联合去甲基化药物治疗高危骨髓增生异常综合征的真实世界疗效与安全性分析

Zhonghua Xue Ye Xue Za Zhi. 2024 Feb 14;45(2):156-162. doi: 10.3760/cma.j.cn121090-20230926-00136.

Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia. Venetoclax 治疗急性髓系白血病的反应生物标志物。

Int J Mol Sci. 2024 Jan 24;25(3):1421. doi: 10.3390/ijms25031421.

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.接受去甲基化药物联合维奈克拉治疗的高危骨髓增生异常综合征的细胞遗传学和分子学与预后的关联

Clin Cancer Res. 2024 Apr 1;30(7):1319-1326. doi: 10.1158/1078-0432.CCR-23-2860.

Recent advances in targeted therapies in acute myeloid leukemia.急性髓系白血病靶向治疗的最新进展。

J Hematol Oncol. 2023 Mar 25;16(1):29. doi: 10.1186/s13045-023-01424-6.

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.成人急性髓系白血病当前治疗方法的更新：强化治疗还是非强化治疗？这是个问题。

Haematologica. 2023 Feb 1;108(2):342-352. doi: 10.3324/haematol.2022.280802.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献